Taken together, our results provide additional scientific evidence that the anti-tumor activity of GEGR is associated with the stimulation of cytotoxicity and apoptosis, alteration of MAPK pathway and Bcl-2/Bax pathway, cell cycle arrest at the G2/M phase, inhibition of NF-κB signaling pathway, suppression of migration ability-associated PI3K/AKT signaling pathway, and decrease of tumor growth in LLC1 cells or LLC1-derived tumors in C57BL/6NKorl mice. This evidence concerns the gene BCL2 and neoplasm.